Michael B Boffa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7760750/publications.pdf

Version: 2024-02-01

87	4,021	136740	118652
papers	citations	32 h-index	62 g-index

87	87	87	3169
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 289-304.	1.1	17
2	Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a). Journal of Lipid Research, 2022, 63, 100216.	2.0	4
3	Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis. Atherosclerosis, 2022, 349, 72-81.	0.4	30
4	Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology. Atherosclerosis, 2022, 349, 92-100.	0.4	31
5	Understanding the ins and outs of lipoprotein (a) metabolism. Current Opinion in Lipidology, 2022, 33, 185-192.	1.2	12
6	Lipoprotein(a): Expanding our knowledge of aortic valve narrowing. Trends in Cardiovascular Medicine, 2021, 31, 305-311.	2.3	13
7	Lipoprotein(a). , 2021, , 547-581.		0
8	Development of an LC-MS/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a). Clinical Chemistry, 2021, 67, 490-499.	1.5	40
9	A Comparative Analysis of the Lipoprotein(a) and Low-Density Lipoprotein Proteomic Profiles Combining Mass Spectrometry and Mendelian Randomization. CJC Open, 2021, 3, 450-459.	0.7	11
10	Lipoprotein Proteomics and Aortic Valve Transcriptomics Identify Biological Pathways Linking Lipoprotein(a) Levels to Aortic Stenosis. Metabolites, 2021, 11, 459.	1.3	14
11	Genetics to the Rescue. Journal of the American College of Cardiology, 2021, 78, 450-452.	1.2	2
12	Lipoprotein (a): Principles from Bench to Bedside. Contemporary Cardiology, 2021, , 363-381.	0.0	0
13	Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a). Journal of Lipid Research, 2020, 61, 1263-1270.	2.0	8
14	Interaction of Autotaxin With Lipoprotein(a) in Patients With Calcific Aortic Valve Stenosis. JACC Basic To Translational Science, 2020, 5, 888-897.	1.9	15
15	Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. Journal of Lipid Research, 2019, 60, 2082-2089.	2.0	35
16	Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nature Reviews Cardiology, 2019, 16, 305-318.	6.1	158
17	Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. Circulation, 2019, 139, 1472-1482.	1.6	196
18	Simultaneous R_{2[*]} and quantitative susceptibility mapping measurement enables differentiation of thrombus hematocrit and age: an in vitro study at 3 T. Journal of NeuroInterventional Surgery, 2019, 11, 1155-1161.	2.0	7

#	Article	IF	Citations
19	New Frontiers in Lp(a)-Targeted Therapies. Trends in Pharmacological Sciences, 2019, 40, 212-225.	4.0	39
20	Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease. Current Opinion in Lipidology, 2019, 30, 428-437.	1.2	6
21	Therapeutic Lowering of Lipoprotein(a). Circulation Genomic and Precision Medicine, 2018, 11, e002052.	1.6	6
22	Lipoprotein(a) in clinical practice: New perspectives from basic and translational science. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 33-54.	2.7	20
23	IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages. Current Problems in Cancer, 2018, 42, 215-230.	1.0	18
24	The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?. Current Opinion in Lipidology, 2018, 29, 259-267.	1.2	11
25	Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE): A Translational, Integrated, and Transdisciplinary Approach. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 606-619.	0.7	12
26	Lipoprotein(a): lodestar for future clinical trials. Lancet, The, 2018, 392, 1281-1282.	6.3	10
27	Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal. Journal of Clinical Lipidology, 2018, 12, 1358-1366.	0.6	30
28	Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins Î±MÎ²2 and Î±VÎ²3. Atherosclerosis, 2018, 275, 11-21.	0.4	6
29	Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells. Thrombosis Research, 2018, 169, 1-7.	0.8	8
30	Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment. Clinical and Experimental Metastasis, 2017, 34, 155-169.	1.7	3
31	The renaissance of lipoprotein(a): Brave new world for preventive cardiology?. Progress in Lipid Research, 2017, 68, 57-82.	5.3	63
32	Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9. PLoS ONE, 2017, 12, e0180869.	1.1	40
33	Is resistance futile? The role of activated thrombin-activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency. Journal of Thrombosis and Haemostasis, 2016, 14, 1600-1602.	1.9	1
34	Identification of a thrombomodulin interaction site on thrombinâ€activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin. Journal of Thrombosis and Haemostasis, 2016, 14, 772-783.	1.9	9
35	Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. BMC Cancer, 2016, 16, 328.	1.1	21
36	Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease. Current Atherosclerosis Reports, 2016, 18, 69.	2.0	9

#	Article	IF	Citations
37	Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?. Journal of Lipid Research, 2016, 57, 745-757.	2.0	181
38	Pro-inflammatory cytokines reduce human TAFI expression via tristetraprolin-mediated mRNA destabilisation and decreased binding of HuR. Thrombosis and Haemostasis, 2015, 114, 337-349.	1.8	13
39	Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor. Journal of Biological Chemistry, 2015, 290, 11649-11662.	1.6	176
40	Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). Journal of Lipid Research, 2015, 56, 2273-2285.	2.0	85
41	Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). Journal of Lipid Research, 2014, 55, 625-634.	2.0	52
42	Lipoprotein(a). Endocrinology and Metabolism Clinics of North America, 2014, 43, 949-962.	1.2	27
43	Lipoprotein(a) as a therapeutic target in cardiovascular disease. Expert Opinion on Therapeutic Targets, 2014, 18, 747-757.	1.5	16
44	Screening for and Management of Elevated Lp(a). Current Cardiology Reports, 2013, 15, 417.	1.3	11
45	Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator. Current Atherosclerosis Reports, 2013, 15, 360.	2.0	32
46	The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity. Thrombosis and Haemostasis, 2013, 109, 1033-1044.	1.8	7
47	Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). Journal of Lipid Research, 2013, 54, 2815-2830.	2.0	174
48	Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone. Blood Coagulation and Fibrinolysis, 2013, 24, 393-404.	0.5	10
49	Apolipoprotein(a) stimulates nuclear translocation of Î²-catenin: a novel pathogenic mechanism for lipoprotein(a). Molecular Biology of the Cell, 2013, 24, 210-221.	0.9	26
50	Apolipoprotein(a) Inhibits In Vitro Tube Formation in Endothelial Cells: Identification of Roles for Kringle V and the Plasminogen Activation System. PLoS ONE, 2013, 8, e52287.	1.1	23
51	Lipoprotein(a). Current Opinion in Lipidology, 2012, 23, 133-140.	1.2	99
52	Regulation of the mouse gene encoding TAFI by TNFÎ±: Role of NFÎºB binding site. Cytokine, 2012, 57, 389-397.	1.4	7
53	Identification of tristetraprolin as a factor that modulates the stability of the TAFI transcript through binding to the 3â€²-untranslated region. Journal of Thrombosis and Haemostasis, 2012, 10, 887-894.	1.9	3
54	Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells. Thrombosis and Haemostasis, 2011, 105, 999-1009.	1.8	15

#	Article	IF	Citations
55	Exon Skipping and Alternative Splicing of CPB2 mRNA in Multiple Cell Types Results in Variants of TAFI That Are Inactive and Not Secretable. Blood, 2011, 118, 1189-1189.	0.6	0
56	Apolipoprotein(a)-Dependent Inhibition of Pericellular Plasminogen Activation Is Mediated by Specific Cellular Receptors. Blood, 2011, 118, 2236-2236.	0.6	0
57	Secretion and antifibrinolytic function of thrombinâ€activatable fibrinolysis inhibitor from human platelets. Journal of Thrombosis and Haemostasis, 2010, 8, 2523-2529.	1.9	34
58	Functional analysis of mutant variants of thrombin-activatable fibrinolysis inhibitor resistant to activation by thrombin or plasmin. Journal of Thrombosis and Haemostasis, 2009, 7, 665-672.	1.9	12
59	Apolipoprotein(a) inhibits the conversion of Gluâ€plasminogen to Lysâ€plasminogen: a novel mechanism for lipoprotein(a)â€mediated inhibition of plasminogen activation. Journal of Thrombosis and Haemostasis, 2008, 6, 2113-2120.	1.9	46
60	Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. Blood, 2008, 111, 183-189.	0.6	42
61	Regulation of Human Thrombin-Activable Fibrinolysis Inhibitor Gene Expression in Megakaryocyte-Like (Dami) and Monocyte/Macrphage- Like (THP-1) Cell Lines. Blood, 2008, 112, 3078-3078.	0.6	0
62	Regulation of the Gene Encoding Human Thrombin-Activable Fibrinolysis Inhibitor by Female Sex Steroids. Blood, 2008, 112, 3077-3077.	0.6	0
63	Molecular analysis of the human thrombin-activatable fibrinolysis inhibitor gene promoter. British Journal of Haematology, 2007, 138, 231-244.	1.2	12
64	Subclinical Vitamin K Deficiency in Hemodialysis Patients. American Journal of Kidney Diseases, 2007, 49, 432-439.	2.1	122
65	Curiouser and curiouser: Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clinical Biochemistry, 2007, 40, 431-442.	0.8	84
66	Lipoprotein(a) as an Emerging Risk Factor for Atherothrombosis. , 2007, , 241-266.		3
67	Lipoprotein(a): A Unique Risk Factor for Cardiovascular Disease. Clinics in Laboratory Medicine, 2006, 26, 751-772.	0.7	86
68	Baboon Lipoprotein(a) Binds Very Weakly to Lysineâ€'Agarose and Fibrin Despite the Presence of a Strong Lysine-Binding Site in Apolipoprotein(a) Kringle IV Type 10. Biochemistry, 2005, 44, 555-564.	1.2	14
69	The Apolipoprotein(a) Component of Lipoprotein(a) Stimulates Actin Stress Fiber Formation and Loss of Cell-Cell Contact in Cultured Endothelial Cells. Journal of Biological Chemistry, 2004, 279, 6526-6533.	1.6	55
70	Stimulation of Vascular Smooth Muscle Cell Proliferation and Migration by Apolipoprotein(a) Is Dependent on Inhibition of Transforming Growth Factor-Î² Activation and on the Presence of Kringle IV Type 9. Journal of Biological Chemistry, 2004, 279, 55187-55195.	1.6	27
71	Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor. Journal of Thrombosis and Haemostasis, 2004, 2, 1969-1979.	1.9	30
72	Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clinical Biochemistry, 2004, 37, 333-343.	0.8	134

#	Article	IF	Citations
73	TAFI and wound healing: closing a knowledge gap. Journal of Thrombosis and Haemostasis, 2003, 1, 2075-2077.	1.9	2
74	A role for apolipoprotein(a) in protection of the low-density lipoprotein component of lipoprotein(a) from copper-mediated oxidation. Archives of Biochemistry and Biophysics, 2003, 412, 186-195.	1.4	8
75	Acute Phase Mediators Modulate Thrombin-activable Fibrinolysis Inhibitor (TAFI) Gene Expression in HepG2 Cells. Journal of Biological Chemistry, 2003, 278, 9250-9257.	1.6	46
76	Inhibition of Plasminogen Activation by Lipoprotein(a). Journal of Biological Chemistry, 2003, 278, 23260-23269.	1.6	99
77	A Role for CCAAT/Enhancer-binding Protein in Hepatic Expression of Thrombin-activable Fibrinolysis Inhibitor. Journal of Biological Chemistry, 2002, 277, 25329-25336.	1.6	22
78	Two Naturally Occurring Variants of TAFI (Thr-325 and Ile-325) Differ Substantially with Respect to Thermal Stability and Antifibrinolytic Activity of the Enzyme. Journal of Biological Chemistry, 2002, 277, 1021-1030.	1.6	148
79	A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood, 2001, 98, 1992-1993.	0.6	112
80	Association of a single nucleotide polymorphism inCPB2encoding the thrombin-activable fibrinolysis inhibitor (TAFI) with blood pressure. Clinical Genetics, 2001, 60, 345-349.	1.0	52
81	Modulation of Fibrin Cofactor Activity in Plasminogen Activation. Annals of the New York Academy of Sciences, 2001, 936, 247-260.	1.8	17
82	Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor. Journal of Biological Chemistry, 2000, 275, 12868-12878.	1.6	99
83	Characterization of the Gene Encoding Human TAFI (Thrombin-Activable Fibrinolysis Inhibitor; Plasma) Tj ETQq1 1 0.784314 rgBT /Ove	1.2	84
84	Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties. Journal of Biological Chemistry, 1998, 273, 2127-2135.	1.6	167
85	A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor. Journal of Biological Chemistry, 1998, 273, 27176-27181.	1.6	329
86	The Solution Phase Interaction between Apolipoprotein(a) and Plasminogen Inhibits the Binding of Plasminogen to a Plasmin-Modified Fibrinogen Surface. Biochemistry, 1997, 36, 10353-10363.	1.2	50
87	Thrombin, Thrombomodulin and TAFI in the Molecular Link Between Coagulation and Fibrinolysis. Thrombosis and Haemostasis, 1997, 78, 386-391.	1.8	223